Chromosomal translocations represent an important prognostic indicator in B-cell chronic lymphocytic leukemia (B-CLL). However, their value had been neither determined in homogeneously treated patients nor compared to that of IgV H mutational status. Sixty-five B-CLL patients were investigated using cytogenetics, interphase fluorescence in situ hybridization (FISH), analysis of IgV H and of TP53 mutational status before treatment with 2-chloro-2 0 -deoxyadenosine (CdA). Translocations (n ¼ 45) were detected in 42% of the patients, including both balanced (n ¼ 12) and unbalanced (n ¼ 33) types. IgV H was mutated in 43% of the patients. Patients with translocations were more heavily pretreated (P ¼ 0.05), presented with more complex karyotypes (Po0.001), 17p abnormalities and TP53 mutations, and had a higher failure rate (59 vs 21% in patients without translocations, P ¼ 0.004). Patients with unbalanced translocations displayed a shorter median treatment-free survival (TFS, 6.9 vs 35.9 months, log rank 22.72, Po0.001) and overall survival (OS, 13.0 vs 68.0 months, log rank 16.51, Po0.001), as compared to patients without translocation. In multivariate analysis, unbalanced translocations were independently associated with therapeutic failure, short TFS and short OS. IgV H mutational status was independently associated with risk of failure and TFS, but not OS. In B-CLL patients treated with CdA, translocations are strong predictors of outcome.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) displays considerable heterogeneity in terms of outcome: some patients may survive for decades without need for therapy, whereas others die from progressive disease within a few years. 1 Prognosis in B-CLL can be routinely estimated using clinical staging systems. 2, 3 More recently, a prognostic value has also been shown for cytogenetic abnormalities, for the mutational status of immunoglobulin heavy-chain variable (IgV H ) region genes, for or CD38 expression, for the lymphocyte doubling time and for serum markers (that is, thymidine kinase, soluble CD23, b2-microglobulin). 1, [4] [5] [6] [7] [8] [9] Identifying the most reliable prognostic indicators, in particular those that determine the need for aggressive and early intervention on an individual basis, remains a major challenge in B-CLL.
Recently, there has been a tendency to replace the more tedious conventional cytogenetic analysis (CCA) by fluorescence in situ hybridization (FISH) on interphase nuclei. Indeed, patients with B-CLL can be categorized into well-defined subgroups with distinct survival according to the type of aberration detected. 7, 10 However, FISH carries an important limitation in that, unlike CCA, it focuses on particular genomic areas -depending on the probe set used -and thus may fail to detect novel markers, complex changes or translocations that are not within the scope of the probe set. Complexity has been associated with in vitro drug resistance and poor outcome in B-CLL. [11] [12] [13] In addition, translocations recently proved to be the prognostic marker with the highest impact for an unfavorable outcome.
14 Still, the significance of translocations on outcome in CLL remains uncertain relative to IgV H mutational status or to treatment outcome after specific drugs. In this report, we sought to assess prognostic significance of CCA in B-CLL patients treated with 2-chloro-2 0 -deoxyadenosine (CdA), and included mutational status in the multivariate analysis.
Materials and methods

Patients
Requirements for inclusion in this study were the following: (i) a confirmed diagnosis of B-CLL by NCIWG criteria; 15 (ii) the availability of a CCA performed before treatment; and (iii) treatment with CdA-containing regimen in clinical studies approved by local ethics committee. Patients analyzed were treated with CdA between November 1991 and July 1997 in three Belgian hematological centers. CdA was synthesized and supplied by Professor J Marchand and Professor L Ghosez (Laboratory of Organic Chemistry, Université Catholique de Louvain, Belgium).
Genetics
Cytogenetic and molecular analyses were centralized at the Center for Human Genetics, Leuven. Shortly before treatment with CdA, standard CCA was performed on peripheral blood and/or bone marrow lymphocytes cultured for 72 h with 12-Otetradecanoylphorbol-13-acetate (TPA). A karyotype was defined as normal when no clonal aberration was found in at least 15 metaphases, and as complex when at least three clonal aberrations were observed. To assess the number of aberrations in a given patient, each numerical and/or structural aberration was taken into account. To assess the number of translocations, both balanced and unbalanced translocations were counted. The distinction between balanced and unbalanced translocations was based on CCA. Inversions, insertions and 'add' (additional material on chromosomes) were considered as translocations, since they imply movement of chromosome segments. When available, follow-up karyotypes were performed. Additional interphase FISH was performed to screen for most common aberrations, for example trisomy 12, deletion 11q, deletion 13q and deletion 17p, using CEP12 (12p11q11), LSI ATM (11q22), D13S319 combined with RB (both on 13q14) and LSI p53 (17p13) combined with CEP17 (17p11q11) probes (Vysis, Bergisch-Gladbach, Germany), respectively. Additional metaphase FISH was carried out in selected patients to clarify cytogenetic aberrations, that is, to assess whether some aberrations were balanced, or to determine the partner chromosome in case of 14q32 aberration. Following amplification with 5 0 VH leader and 3 0 JH primers, 16 PCR fragments were sequenced and analyzed for IgV H status using the IMGT/V-QUEST database (http://imgt.cines.fr). Sequences were considered as unmutated when exhibiting at least 98% homology with the closest germ line. Mutations of the TP53 gene were assessed by PCR followed by denaturing gradient gel electrophoresis (DGGE) as previously described (see Supplementary Table 1) . 17 
Statistical analysis
Statistical analyses were performed using the SPSS12 and the Prism4 statistical softwares. Data are reported as numbers and percentages for discrete variables, and as median and range for continuous variables according to whether normal distributed or not. All tests were two sided and the statistical significance level was set to 0.05. Discrete variables were compared between patients with or without translocations using a w 2 test when the minimum expected value was greater than 5, and the Fisher's exact test otherwise. Continuous variables were compared using Student's t-test when distributions were symmetric and MannWhitney U test otherwise. Parametric tests were performed for normal-distributed variables. Normality was accepted when seven different normality tests were not significant and when the normal probability plot showed a line across points. These tests were also used to compare the incidence of genetic abnormalities and response rates between previously treated (PRT) and untreated (UNT) patients. End points of the study were response, treatment-free survival (TFS) and overall survival (OS). TFS was defined as the interval from end of CdA treatment to the start of next therapeutic line. OS was calculated from study inclusion until death or last follow-up. Survival curves were estimated using the Kaplan-Meier method. The log-rank test was used to compare survivals. Differences with respect to response, TFS and OS attributed to prognostic factors were analyzed by multivariate Cox regression. The variables included were as follows: presence and type of cytogenetic aberrations before CdA (detected by CCA and/or interphase FISH), age, gender, Binet stage, type and number of prior antileukemic therapies, time between diagnosis and inclusion, blood counts, lactic dehydrogenase (LDH) level, IgV H mutational status and the number of courses of CdA. Contribution to prognosis was expressed as the multiplicative increase in mortality (hazards ratio, HR) associated with a one-unit increase in covariate. Because of the heterogeneity of our study group (PRT and UNT patients), we introduced previous treatment before CdA and unbalanced translocation as initial variables in our Cox regression model. All other covariates were tested for significant improvement, conditionally to those maintained variables.
Results
Patients' characteristics
The median age was 62 years. Thirty-one (48%) patients were UNT and 34 (52%) were PRT. Among the latter, 65% were refractory to their last treatment, and the median number of prior lines was 2 (range: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 
Genetic findings
Cytogenetic analysis performed before therapy with CdA was normal in 23 and disclosed no mitoses in 2 patients. Chromosomal abnormalities were found in 40 (62%) patients and were encountered more frequently in the PRT (25 of 34) as compared to UNT group (15 of 31, Po0.04). However, there was no significant difference in individual abnormalities and complex karyotypes among UNT and PRT patients (see Supplementary Table 2 ). Single, double and complex aberrations were observed in 16 (25%), 11 (17%) and 13 (20%) patients, respectively. The most frequent were abnormalities of the short arm of chromosome 17 (visible loss of 17p in 11, including five cases with der(17;18)(q10;q10)) and abnormalities of the long arm of chromosome 11 (del(11q) in 10, and other structural aberration of 11q in one patient). Deletions of Table 1 Characteristics of the patients (n ¼ 65) Prognostic significance of translocations in B-CLL E Van Den Neste et al the long arm of chromosome 13 (del(13q)) were observed in four patients, and translocations involving 13q in five patients. Other recurrent changes were as follows: abnormalities of 18p (n ¼ 8, including five cases with der(17;18)(q10;q10)), abnormalities of 14q32 (n ¼ 6, including t(14;19)(q32;q13) with involvement of the immunoglobulin heavy chain (IGH) and BCL3 genes in two, t(2;14)(p13;q32) with involvement of IGH and breakpoints on 2p13 distinct from BCL11A and REL in two, t(14;17)(q32;p11) in one, and inv(14)(q12q32) in one patient, the latter two involving IGH and undetermined partner genes), trisomy 12 (n ¼ 5) and aberrations involving 6q (del(6q) in two, and other structural aberration of 6q in two patients). Less frequent changes were as follows: aberrations of 6p (n ¼ 3, including one der(6p), one t(1;6)(p35;p25) and one add(6)(p22)), trisomy X (n ¼ 3), add(10p) (n ¼ 2) and add(2p) (n ¼ 2). The respective frequencies of 17p versus 13q aberrations in this study probably reflect the inclusion of advanced patients. The incidence of complex karyotypes was not different between PRT (n ¼ 9, 26.5%) and UNT patients (n ¼ 4, 12.9%, P ¼ 0.172). Translocations (n ¼ 45) were detected in 27 (42%) of the patients, and included both balanced (n ¼ 12) and unbalanced (n ¼ 33) types (Table 2 ). Most breakpoints involved regions recurrently involved in CLL, that is, 17p, 14q and 13q (Table 2 , details on the breakpoints are available on Supplementary Figure 1 ). Except for those affecting the region 14q32, which were balanced (six cases), the majority of translocations were associated with deletions located in regions previously described as recurrently deleted in CLL, such as 17p (n ¼ 9), 13q (n ¼ 4), 11q (n ¼ 1), 6q (n ¼ 2) or regions often involved in B-cell lymphoma in general, for example, 18p (n ¼ 9, with recurrent loss of the entire p arm), 6p (n ¼ 2), 1p
. Interestingly, 4/5 of apparently balanced translocations involving 13q14 were associated with microdeletion of the D13S319 and/or RB1 locus, as demonstrated by FISH analysis. Gains associated with translocations were uncommon and involved the region 12q (n ¼ 2), 16p (n ¼ 1) and 9q (n ¼ 1). Patients with translocations were more likely PRT (P ¼ 0.05), had received more previous treatments (P ¼ 0.05) and presented more often with complex karyotypes (Po0.001), 17p aberrations (Po0.001) and TP53 mutations (Po0.001) ( Table 3) . Translocations were observed in 29% (9/31) of UNT and 53% (18/34) of PRT patients (P ¼ 0.05, Supplementary Table 2 ). Follow-up cytogenetics was performed in 53 patients. Clonal evolution was observed in 19 (36%) of them, occurring both in translocation carriers (7/21, 33%) and in patients without translocations (12/32, 37%). Briefly, recurrent changes observed during evolution involved 11q (n ¼ 6), 14q (n ¼ 4, including two patients with t(2;14)(p13;q32)), 17p (n ¼ 2) and 13q (n ¼ 2, including one patient with a previously cryptic deletion). A detailed description of patients with clonal evolution is provided as Supplementary Table 3 .
Interphase FISH could be performed in 43 patients (66%), that is, in 15/25 patients (60%) with normal karyotype or karyotype failure and in 28/40 patients (70%) with aberration(s). It was concordant with CCA for the regions 12p11q11, 11q22 and 17p13. The sole discrepancies implied the region 13q14. Indeed, microdeletions involving D13S319 and/or RB1 were observed in eight patients with either a normal karyotype (n ¼ 3) or aberrations apparently not involving chromosome 13 (n ¼ 5) and, as mentioned above, in four patients with apparently balanced aberrations involving 13q.
IgV H mutational status was assessed in 61 patients: 26 (43%) were mutated and 35 (57%) unmutated. The majority of cases utilized members of the V H 3 (n ¼ 30), V H 1 (n ¼ 21) and V H 4 (n ¼ 12) families, and V H 3-21 usage was observed in two cases. Fifteen of 61 patients (25%) showed TP53 mutations. Seven of the mutations were missense and two were nonsense. One patient displayed both a splice site mutation located 5 0 of exon 7 and a deletion of one codon in exon 9. Six mutations occurred in exon 7, one in exon 4, one in exon 5 and one in exon 8. Five patients displayed silent mutations, involving either exon 4 (n ¼ 1) or exon 6 (n ¼ 4).
Response after CdA
The overall response rate was 57%, with complete response (CR) in 18% and partial response (PR) in 38%. The overall response rate in UNT and PRT patients was 74% (29% CR) and 41% (9% CR, P ¼ 0.007), respectively. In univariate analysis, the variables associated with risk of failure were as follows: hemoglobin (odds ratio (OR): 0. 
TFS after CdA
The median TFS of the entire population was 23.3 months (range: 0.6-105.7). The median TFS was 40.1 months (range: 1.5-105.7) and 11.9 months (range: 0.7-96.8, log rank 19.31, Po0.001) in UNT and PRT patients, respectively. Median TFS in patients with normal karyotype, 1-2 abnormalities or complex karyotype was 64.1 months (range: 1.5-105.7), 18.8 months (range: 2.5-97.6) and 4.4 months (range: 0.7-33.7), respectively (log rank 29.59, Po0.001) (Figure 1a) . Median TFS in patients without translocations, with balanced translocations or with unbalanced translocations was 35.9 months (range: 1.5-105.7), 17.54 months (range: 4.8-78.1) and 6.9 months (range: 0.7-53.1), respectively (log rank 22.72, Po0.001) (Figure 1b) . Patients with unbalanced translocations had a significantly lower TFS (log rank 12.93, Po0.01) even after exclusion of those also carrying a 17p abnormality (see Supplementary  Figure 2 ). We also observed that TFS was shorter in patients carrying a translocation, whether they belonged to the PRT or UNT subgroups (displayed in Supplementary Figure 3) . Median TFS in patients with mutated or unmutated IgV H genes was 57.8 months (range: 5.6-102.2) and 16.6 months (range: 0.7-96.8, log rank 18.01, Po0.001, not shown). As shown in Figure 2a , median TFS in patients with mutated IgV H genes was significantly different according to the absence (median not reached) or the presence (18.7 months, range: 5.6-78.1, log rank: 7.174, P ¼ 0.007) of translocations. Similarly, median TFS in unmutated patients was significantly longer without associated translocation (23.8 months, range: 1.5-96.8, log rank 7.329, P ¼ 0.007) than if a translocation was present (5.3 months, range: 0.7-53.1, Figure 2b ).
Covariates significantly (Po0.05) associated with TFS in univariate analysis were hemoglobin, LDH, prior therapy with Prognostic significance of translocations in B-CLL Table 4 , indicators independently correlated with TFS in the multivariate analysis were unbalanced translocations, Prognostic significance of translocations in B-CLL E Van Den Neste et al unmutated IgV H genes, time between diagnosis and inclusion, hemoglobin, abnormal karyotype and 17p aberrations. Of note, the presence of unbalanced translocations and previous treatment did not significantly interact.
OS after CdA
The median OS of the entire population was 56.5 months (range: 0.9-107.3). In UNT patients, median OS was not reached (range: 3.9-105.7, 100-month survival probability ¼ 60%). In PRT patients, median OS was 32.8 months (range: 3.9-107.3, log rank 15.4, Po0.001). In patients with a normal karyotype, median OS was not attained after a median follow-up of 44 months. Their 100-month survival probability was 53%. The median OS in patients with one or two abnormalities was 59.1 months (range: 3.9-107.3) and in patients with X3 abnormalities it was 9.8 months (range: 0.9-62.0, log rank 29.3, Po0.001, Figure 1c) . Median OS in patients without translocation, with balanced translocation and with unbalanced translocation was 94.0 months (range: 3.8-105.7), 73.6 months (range: 9.6-83.7) and 13.0 months (range: 0.9-107.3), respectively (log rank 18.04, Po0.001, Figure 1d) . As for TFS, OS of patients with unbalanced translocation but no 17p aberrations was significantly shorter (log rank 9.7, Po0.01) than that of patients with balanced translocation or without translocation (Supplementary Figure 2) . OS was shorter in patients with translocations irrespective of their pretreatment status (PRT or UNT subgroups, see Supplementary Figure 3 ). As shown in Figure 2c , median OS in patients with mutated IgV H genes and no translocation was not reached (100-month survival probability ¼ 79%), whereas OS in mutated patients with translocation was significantly lower (33.8 months, range: 5.6-83.7, log rank 12.54, Po0.001). Median OS in unmutated patients with or without translocation was not significantly different ( Figure 2d ). Baseline covariates significantly associated (Po0.05) with OS in univariate analysis were hemoglobin, LDH, prior treatment with alkylating agents or with fludarabine, PRT status, interval between diagnosis and inclusion, Binet stage, abnormal karyotype, complex karyotype, 17p abnormalities, TP53 mutations, unmutated IgV H genes, translocations and unbalanced translocations. As shown in Table 5 , indicators independently correlating with OS in the multivariate analysis were unbalanced translocations, previous treatment, abnormal karyotype, age and LDH. Of note, the first two parameters (presence of unbalanced translocations and previous treatment) did not significantly interact.
Discussion
In this study, we demonstrate that occurrence of unbalanced translocations is a strong and independent factor predicting lack of response, short TFS and short OS in B-CLL patients treated with CdA. This is the first report that correlates the presence of translocations with outcome in B-CLL after a specific treatment. In addition, the value of unbalanced translocations could be compared to that of one of the most important prognostic factors in B-CLL, that is, IgV H mutational status. The multivariate analysis also included a broad range of factors with prognostic impact in B-CLL, including clinical data, type and number of cytogenetic aberrations detected by FISH or CCA, and TP53 mutations. This analysis shows that unbalanced translocations override other prognostic factors -especially IgV H mutational status -in predicting response and TFS. It is also the sole genetic parameter with independent prognostic value with respect to OS. The prognostic value of translocation remained significant on TFS and OS even after excluding patients carrying 17p aberrations (which exclusively occurred in translocated patients). Overall, our results accord with the recent report of Mayr et al.
14 showing that translocations, both balanced and unbalanced, critically determine a new prognostic subgroup with inferior TFS and OS. Here, we did not find a negative prognostic impact of balanced translocations on OS, but this should be confirmed in a larger trial.
We also observed that the translocation status may further categorize patients with similar IgV H mutational status. Indeed, mutated patients with translocation displayed significantly shorter TFS and OS than mutated patients without translocations. In addition, in unmutated patients with translocations, TFS (but not OS) was worse compared to that in unmutated patients without translocations. These data correlate with the results of Mayr et al.
14 showing that patients with the favorable 13q deletion, or conversely with the unfavorable 11q deletion, have different TFS rates according to the presence or absence of translocations.
In the present series, CCA was successful in 97% of the samples, and clonal cytogenetic abnormalities were detected in 61% of patients, which is higher than in previous reports on CCA in CLL. 12, 18, 19 This is due to the systematic use of a classical B-cell mitogen (TPA) to overcome the low mitotic index of the neoplastic B cells. Still, this rate of detection remains inferior to that of FISH. 10 Interestingly, in this study, interphase FISH results did not profoundly modify the hierarchical categorization of patients based on CCA. Indeed, the sole aberration that was missed by CCA was microdeletion of the 13q14 region, otherwise considered as favorable. Several studies have shown that the success rate of CCA in B-CLL might be further increased, up to that of FISH, by stimulation of B cells with CD40 ligand (CD40L) or CpG-oligodeoxynucleotides (CpG-ODN) and interleukin-2.
14,20 Using the latter method, Dicker et al. 21 have recently shown that chromosome banding can reveal a substantial amount of information, including complex karyotypes and unbalanced translocations, in addition to those detected by the FISH probes. Interestingly, they observed that translocations correlated to an unmutated IgV H status (P ¼ 0.06), which we did not observe. Similar to us, they described microdeletions (involving mainly 13q) missed by CCA. These studies show that information provided by interphase and metaphase analysis in B-CLL is not redundant.
Our study emphasizes that translocations can be detected in an important proportion (42%) of patients with B-CLL. This percentage is higher than that recently reported by Mayr et al. 14 and Dicker et al., 21 possibly reflecting the selection of more advanced patients. Most breakpoints involved regions recurrently involved in CLL. Translocations tended to occur more frequently in PRT patients (53%) than in UNT patients (29%), raising the hypothesis that translocations might be treatmentassociated secondary events. Both Cox regression and KaplanMeier analysis indicate that the impact of translocation is not different in UNT or PRT patients. It is worth mentioning, however, that despite the commonly accepted postulate that karyotypes are rather stable in B-CLL over time, 22 other studies have found a higher incidence of karyotypic evolution, including in UNT patients. 23, 24 We observed clonal evolution in about 30% of patients.
An additional benefit of metaphase CCA is that it is informative on the number of chromosomal abnormalities. We show that B-CLL patients with complex karyotype have shorter TFS and OS as compared to those with fewer abnormalities, confirming previous clinical studies, [12] [13] [14] and in vitro data correlating karyotype complexity with resistance to drugs, including CdA. 11 However, as noted in the reports mentioned above, karyotype complexity did not retain an independent prognostic value in the multivariate analysis.
In conclusion, the statement according to which CCA is of limited value in risk categorization of B-CLL patients should be revised. Indeed, this technique provides crucial information on the presence and type of translocations, which are disregarded by FISH. In addition, poor sensitivity of CCA, usually felt as a From likelihood ratio test at each entry step (three steps of selection).
Prognostic significance of translocations in B-CLL E Van Den Neste et al limitation of this technique, can be improved by appropriate procedures. The study of translocations could also contribute to a better understanding of tumorigenic events in B-CLL.
